Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yoshie Morimoto

Showing results (11-20 of 32) with videos related to

Pageof 4
Sort By:
Translational Lung Cancer Research|February 11, 2021
Prognostic factors in older patients with wild-type epidermal growth factor receptor advanced non-small cell lung cancer: a multicenter retrospective studyYurie Seto, Yoshiko Kaneko, Takako Mouri, et al.
Anticancer Research|March 31, 2018
Feasibility Study of Sequentially Alternating EGFR-TKIs and Chemotherapy for Patients with Non-small Cell Lung CancerYoshizumi Takemura, Yusuke Chihara, Yoshie Morimoto, et al.
International Immunopharmacology|April 18, 2022
A real-world study on the safety of the extended dosing schedule for nivolumab and pembrolizumab in patients with solid tumorsKenji Morimoto, Tadaaki Yamada, Yoshie Morimoto, et al.
Thoracic Cancer|November 18, 2021
Impact of docetaxel plus ramucirumab in a second-line setting after chemoimmunotherapy in patients with non-small-cell lung cancer: A retrospective studyMasaki Ishida, Kenji Morimoto, Tadaaki Yamada, et al.
Anticancer Research|October 3, 2022
Efficacy and Safety of Paclitaxel/nab-paclitaxel Chemotherapy for Patients With Relapsed Small Cell Lung CancerYohei Matsui, Tadaaki Yamada, Kenji Morimoto, et al.
Cancer Medicine|January 14, 2022
Heterogeneity among tumors with acquired resistance to EGFR tyrosine kinase inhibitors harboring EGFR-T790M mutation in non-small cell lung cancer cellsYuki Katayama, Tadaaki Yamada, Shinsaku Tokuda, et al.
Frontiers in Oncology|April 9, 2021
Immune-Related Adverse Events Are Associated With Clinical Benefit in Patients With Non-Small-Cell Lung Cancer Treated With Immunotherapy Plus Chemotherapy: A Retrospective StudyKenji Morimoto, Tadaaki Yamada, Chieko Takumi, et al.
Frontiers in Oncology|June 14, 2021
The Impact of VEGF Inhibition on Clinical Outcomes in Patients With Advanced Non-Small Cell Lung Cancer Treated With Immunotherapy: A Retrospective Cohort StudyKeiko Tanimura, Tadaaki Yamada, Ayaka Omura, et al.
JTO Clinical and Research Reports|July 5, 2022
Efficacy and Safety of Programmed Death-Ligand 1 Inhibitor Plus Platinum-Etoposide Chemotherapy in Patients With Extensive-Stage SCLC: A Prospective Observational StudyKenji Morimoto, Tadaaki Yamada, Takayuki Takeda, et al.
Cancer Letters|September 17, 2021
Inhibition of c-Jun N-terminal kinase signaling increased apoptosis and prevented the emergence of ALK-TKI-tolerant cells in ALK-rearranged non-small cell lung cancerKeiko Tanimura, Tadaaki Yamada, Mano Horinaka, et al.
Pageof 4

Showing results (11-20 of 32) with videos related to

Sort By:
Pageof 4
Translational Lung Cancer Research|February 11, 2021
Prognostic factors in older patients with wild-type epidermal growth factor receptor advanced non-small cell lung cancer: a multicenter retrospective studyYurie Seto, Yoshiko Kaneko, Takako Mouri, et al.
Anticancer Research|March 31, 2018
Feasibility Study of Sequentially Alternating EGFR-TKIs and Chemotherapy for Patients with Non-small Cell Lung CancerYoshizumi Takemura, Yusuke Chihara, Yoshie Morimoto, et al.
International Immunopharmacology|April 18, 2022
A real-world study on the safety of the extended dosing schedule for nivolumab and pembrolizumab in patients with solid tumorsKenji Morimoto, Tadaaki Yamada, Yoshie Morimoto, et al.
Thoracic Cancer|November 18, 2021
Impact of docetaxel plus ramucirumab in a second-line setting after chemoimmunotherapy in patients with non-small-cell lung cancer: A retrospective studyMasaki Ishida, Kenji Morimoto, Tadaaki Yamada, et al.
Anticancer Research|October 3, 2022
Efficacy and Safety of Paclitaxel/nab-paclitaxel Chemotherapy for Patients With Relapsed Small Cell Lung CancerYohei Matsui, Tadaaki Yamada, Kenji Morimoto, et al.
Cancer Medicine|January 14, 2022
Heterogeneity among tumors with acquired resistance to EGFR tyrosine kinase inhibitors harboring EGFR-T790M mutation in non-small cell lung cancer cellsYuki Katayama, Tadaaki Yamada, Shinsaku Tokuda, et al.
Frontiers in Oncology|April 9, 2021
Immune-Related Adverse Events Are Associated With Clinical Benefit in Patients With Non-Small-Cell Lung Cancer Treated With Immunotherapy Plus Chemotherapy: A Retrospective StudyKenji Morimoto, Tadaaki Yamada, Chieko Takumi, et al.
Frontiers in Oncology|June 14, 2021
The Impact of VEGF Inhibition on Clinical Outcomes in Patients With Advanced Non-Small Cell Lung Cancer Treated With Immunotherapy: A Retrospective Cohort StudyKeiko Tanimura, Tadaaki Yamada, Ayaka Omura, et al.
JTO Clinical and Research Reports|July 5, 2022
Efficacy and Safety of Programmed Death-Ligand 1 Inhibitor Plus Platinum-Etoposide Chemotherapy in Patients With Extensive-Stage SCLC: A Prospective Observational StudyKenji Morimoto, Tadaaki Yamada, Takayuki Takeda, et al.
Cancer Letters|September 17, 2021
Inhibition of c-Jun N-terminal kinase signaling increased apoptosis and prevented the emergence of ALK-TKI-tolerant cells in ALK-rearranged non-small cell lung cancerKeiko Tanimura, Tadaaki Yamada, Mano Horinaka, et al.
Pageof 4